Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
FP16 - Tumor Biology and Systems Biology: Basic and Translational Science
- Type: Posters (Featured)
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
- Presentations: 5
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
FP16.03 - Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
00:00 - 00:00 | Presenter: Myung-Ju Ahn
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P15.01 - Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- Presentations: 18
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P47.08 - A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading...
-
+
MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma
- Type: Mini Oral
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
- Presentations: 8
- Coordinates: 9/08/2021, 10:45 - 11:45, Program Auditorium
-
+
MA04.03 - A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21)
10:55 - 11:00 | Presenter: Hyun Ae Jung
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
IS08 - Industry Symposium Sponsored by Eli Lilly And Company: Personalizing and Optimizing Treatment for Metastatic NSCLC Patients with EGFR Mutations - Is There More We Can Do?
- Type: Industry Supported Symposium
- Track: N.A.
- Presentations: 6
- Coordinates: 9/10/2021, 05:45 - 06:45, Industry Symposium Auditorium via Industry Hub
-
+
IS08.04 - Identifying the Clinical and Disease Characteristics of the High Risk Patient, What Is the Science Telling Us?
06:15 - 06:25 | Presenter: Myung-Ju Ahn
- Abstract
No abstract available for this presentation
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 9
- Coordinates: 9/13/2021, 17:30 - 18:30, Program Auditorium
-
+
MA13.03 - Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial
17:40 - 17:45 | Presenter: Jiyun Lee
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
ES20 - Caveats, Challenges, and Controversies in Immunotherapy of Lung Cancer: Phase II and Phase III Trials*
- Type: Education Session
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 5
*Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.- Moderators:David R. Gandara
- Coordinates: 9/14/2021, 20:30 - 21:05, Program Auditorium
-
+
ES20.01 - The Statistical Imperatives of Immunotherapy Research
20:30 - 20:32 | Presenter: Mary Redman
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES20.02 - Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer
20:32 - 20:34 | Presenter: Sanjay Popat
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES20.03 - Open and Unanswered Questions for Treatment and Needed Studies: What We Do and Do Not Know
20:34 - 20:36 | Presenter: Nick Pavlakis
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES20.04 - Challenges to Expand Who Gets Immunotherapy
20:36 - 20:38 | Presenter: Lyudmila Bazhenova
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
ES20.05 - Live Discussion with Speakers
20:38 - 21:05
- Abstract
No abstract available for this presentation